Evolus shares rise on upbeat 2024 revenue outlook

Vadym Terelyuk/iStock via Getty Images Evolus ( NASDAQ: EOLS ) announced on Tuesday prelim Q4 revenue of ~$61M, an increase of 40% year over year. Shares of EOLS jumped 5.5% in after hours trading. Analysts on average expect Q4 revenue of $56.5M. The company reported prelim full year 2023 revenue of ~$202M, which marks a 36% jump.

Analysts on average expect 2023 revenue of $198M. EOLS expects 2024 revenue to be between $255M and $265M, higher than analysts' expectation of $253.3M. The company sees 2024 non GAAP operating expenses to be between $185M and $190M. EOLS expects non GAAP operating income to be positive in 2025.

Press Release More on Evolus Evolus: Negative Earnings Continue Despite Sustained Top Line Growth Evolus, Inc. (EOLS) Q3 2023 Earnings Call Transcript Public Citizen petitions FDA for stricter warnings against Botox, similar drugs Evolus GAAP EPS of $0.30 misses by $0.01, revenue of $50M beats by $5.62M Seeking Alpha’s Quant Rating on Evolus.